These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18087184)

  • 1. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
    Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
    Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
    Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
    Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
    Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
    Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
    Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
    Srinivas S; Guardino AE
    BJU Int; 2005 Sep; 96(4):536-9. PubMed ID: 16104906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
    Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
    Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose vitamin K3 infusion in advanced hepatocellular carcinoma.
    Sarin SK; Kumar M; Garg S; Hissar S; Pandey C; Sharma BC
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1478-82. PubMed ID: 16911696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
    Nakazawa T; Adachi S; Kitano M; Isobe Y; Kokubu S; Hidaka H; Ono K; Okuwaki Y; Watanabe M; Shibuya A; Saigenji K
    Oncology; 2007; 73(1-2):90-7. PubMed ID: 18337620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
    Ch'ang HJ; Hsu C; Chen CH; Chang YH; Chang JS; Chen LT
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):817-25. PubMed ID: 21277098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.